Fredun Pharma
BSE: FREDUN · Pharmaceuticals
Snapshot
Unlock Fredun Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Fredun Pharmaceuticals Ltd. is a Mumbai-based manufacturer and distributor of pharmaceutical, nutraceutical, herbal, and dietary supplement products. The company also maintains a dedicated portfolio of animal healthcare solutions.
Business Model
The company generates revenue through the manufacturing and sale of diverse healthcare products, catering to both human and animal health markets. It operates as a pharmaceutical entity with a focus on diversified health supplements.
Growth Outlook
Growth is expected to be driven by the expanding demand for nutraceuticals and dietary supplements in both domestic and international markets. The company continues to leverage its established manufacturing capabilities to scale its product offerings.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical regulations and quality standards which, if not met, could lead to product recalls or manufacturing suspensions.
- Market Competition. The pharmaceutical and nutraceutical sectors are highly competitive, potentially impacting profit margins and market share.
- Raw Material Price Volatility. Fluctuations in the cost of active pharmaceutical ingredients and raw materials can adversely affect the company's operational profitability.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Fredun Pharma and 5,000+ companies — free.
Key Metrics
P/E
13.5x
Q4 FY26 · consolidated
EV/EBITDA
7.5x
Q4 FY26 · consolidated
NET PROFIT MARGIN
5.1%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.8x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Fredun PharmaFREDUN | 920 | 13.51 | 7.46 | — | 14.9% | 21.3% | 40.9% | +4.5% |
Kilitch DrugsKILITCH | 1,091 | 13.45 | 14.88 | 18.7% | 20.3% | 13.3% | 17.3% | -60.2% |
Syncom Formul.SYNCOMF | 1,082 | 15.39 | 11.81 | 5.0% | 22.2% | 21.2% | 27.4% | -27.3% |
Bajaj HealthcareBAJAJHCARE | 1,040 | 54.68 | 12.96 | 12.6% | 18.3% | 3.3% | 9.0% | -28.9% |
Fermenta Biotec.FERMENTA | 1,000 | 18.39 | 11.42 | 11.9% | 23.3% | 19.0% | 26.1% | +21.4% |
WanburyWANBURY | 842 | 16.70 | 13.12 | 8.8% | 16.6% | 82.1% | 34.7% | +27.6% |
As of Q4 FY26
Financials
Fredun Pharma
BSE: FREDUN · Pharmaceuticals
Snapshot
Unlock Fredun Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Fredun Pharmaceuticals Ltd. is a Mumbai-based manufacturer and distributor of pharmaceutical, nutraceutical, herbal, and dietary supplement products. The company also maintains a dedicated portfolio of animal healthcare solutions.
Business Model
The company generates revenue through the manufacturing and sale of diverse healthcare products, catering to both human and animal health markets. It operates as a pharmaceutical entity with a focus on diversified health supplements.
Growth Outlook
Growth is expected to be driven by the expanding demand for nutraceuticals and dietary supplements in both domestic and international markets. The company continues to leverage its established manufacturing capabilities to scale its product offerings.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical regulations and quality standards which, if not met, could lead to product recalls or manufacturing suspensions.
- Market Competition. The pharmaceutical and nutraceutical sectors are highly competitive, potentially impacting profit margins and market share.
- Raw Material Price Volatility. Fluctuations in the cost of active pharmaceutical ingredients and raw materials can adversely affect the company's operational profitability.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Fredun Pharma and 5,000+ companies — free.
Key Metrics
P/E
13.5x
Q4 FY26 · consolidated
EV/EBITDA
7.5x
Q4 FY26 · consolidated
NET PROFIT MARGIN
5.1%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.8x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26